£96 M

SUMM.L Mkt cap, 31-Oct-2017

£2.3 M

Summit Therapeutics Revenue FY, 2017
Summit Therapeutics Net income (FY, 2017)-21.4 M
Summit Therapeutics EBITDA (FY, 2017)-24.8 M
Summit Therapeutics EBIT (FY, 2017)-24.9 M
Summit Therapeutics Cash, 31-Jan-201728.1 M

Summit Therapeutics Financials

Summit Therapeutics Income Statement

Annual

GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3 m1.8 m189 k763 k1.8 m1.8 m1.8 m2.1 m1.5 m2.3 m

Revenue growth, %

16%(32%)

Cost of goods sold

1.6 m1.1 m

Gross profit

1.4 m773 k

Gross profit Margin, %

46%42%

Operating expense total

13.2 m25.1 m5.9 m6.7 m4.8 m6.4 m(4.9 m)14.9 m27.2 m

EBITDA

(10.1 m)(19.9 m)(5.1 m)(5.8 m)(2.8 m)(3.6 m)6.7 m(12.7 m)(20.3 m)(24.8 m)

EBITDA margin, %

(334%)(1084%)(2686%)(755%)(159%)(198%)365%(590%)(1399%)(1076%)

EBIT

(11.8 m)(24.3 m)(5.8 m)(5.9 m)(3 m)(4.6 m)6.7 m(12.7 m)(20.3 m)(24.9 m)

EBIT margin, %

(388%)(1330%)(3048%)(777%)(170%)(252%)364%(592%)(1402%)(1079%)

Pre tax profit

(11 m)(24.1 m)(5.8 m)(5.9 m)(3 m)(4.6 m)(6.7 m)(12.7 m)(23.2 m)(25.7 m)

Income tax expense

911 k1.7 m(372 k)1.2 m304 k341 k607 k1.3 m3.1 m4.3 m

Net Income

(10.1 m)(22.4 m)(6.2 m)(4.7 m)(2.7 m)(4.2 m)(6.1 m)(11.4 m)(20.1 m)(21.4 m)

Summit Therapeutics Balance Sheet

Annual

GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.1 m2.7 m6.1 m3.3 m2.1 m3.4 m2 m11.3 m16.3 m28.1 m

Accounts Receivable

189 k651 k41 k32 k47 k51 k

Inventories

337 k391 k

Current Assets

12.7 m5.4 m6.6 m3.7 m2.6 m4.2 m3.1 m15.2 m20.8 m33.3 m

PP&E

4.3 m3.7 m335 k260 k149 k23 k43 k55 k83 k116 k

Goodwill

4.2 m4.1 m4.1 m

Total Assets

34.9 m13.9 m11.5 m5.1 m3.9 m4.4 m7.3 m19.4 m25.1 m37.6 m

Accounts Payable

1.8 m675 k149 k332 k372 k254 k349 k1.2 m716 k906 k

Current Liabilities

3.4 m1.9 m1.1 m1.2 m1.3 m1.5 m1.9 m3.7 m3.2 m10.9 m

Non-Current Liabilities

4.3 m3.5 m2.1 m205 k205 k664 k709 k5.8 m30.2 m

Total Debt

188 k

Total Liabilities

7.7 m5.4 m3.2 m1.4 m1.5 m1.5 m2.5 m4.4 m9 m41.1 m

Additional Paid-in Capital

5 m5.6 m6.9 m6.9 m7.1 m8.8 m10.1 m411 k613 k618 k

Retained Earnings

(10.1 m)(22.4 m)(6.2 m)(4.7 m)(2.7 m)(4.2 m)(6.1 m)(11.4 m)(20.1 m)(21.4 m)

Total Equity

27.2 m8.6 m8.3 m3.7 m2.4 m2.9 m4.8 m15 m16.1 m(3.5 m)

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.3 x1.6 x1.4 x1.4 x1.6 x1.5 x1.5 x1.3 x1.6 x-10.8 x

Summit Therapeutics Cash Flow

Annual

GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(10.1 m)(22.4 m)(6.2 m)(4.7 m)(2.7 m)(4.2 m)(6.1 m)(11.4 m)(20.1 m)(21.4 m)

Cash From Operating Activities

8.1 m(10.1 m)(3.1 m)(2.7 m)(2.4 m)(3.2 m)(5.9 m)(11.3 m)(17.2 m)12.1 m

Cash From Financing Activities

633 k3.6 m5 m14 k1.4 m4.6 m4.5 m20.5 m22.1 m413 k

Net Change in Cash

8.2 m(7.4 m)3.4 m(2.8 m)(1.2 m)1.3 m(1.3 m)9.2 m4.9 m12.5 m

Income Taxes Paid

607 k1.3 m3.1 m

Summit Therapeutics Ratios

GBPY, 2017

Revenue/Employee

56.9 k

Financial Leverage

-10.8 x
Report incorrect company information